^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR Q787Q

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2years
    Two independent variants of epidermal growth factor receptor associated with risk of glioma in a Korean population. (PubMed, Sci Rep)
    This study is the first to show evidence that functional variants of EGFR, namely, rs2227983 (K521R) and rs1050171 (Q787Q), are associated with an increased risk of glioma in the Korean population. Future work should confirm the functional association between EGFR variants and glioma.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR Q787Q
    over2years
    Prevalence of the synonymous EGFR Q787Q variant in Mexican patients with non-small cell lung cancer (ESMO 2022)
    Patients with Q787Q (+) received platinum-based chemotherapy in 66.7%, median progression-free survival (PFS) and overall survival (OS) were significantly shorter (7.0 vs. 9.7 months p= 0.010) and (5.6 vs. 20.5 months p< 0.001), respectively. Conclusions The synonymous EGFR Q787Q (+) variant represent a worse prognosis factor to platinum-based chemotherapy in Mexican population of NSCLC.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR exon 18 mutation • EGFR Q787Q
    over2years
    EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs. (PubMed, Front Oncol)
    Our study demonstrated that EGFR Q787Q polymorphism is a germline variant in the general population. It is a protective predictor of overall survival in patients with stage IV EGFR-mutated lung adenocarcinoma treated with TKIs.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • EGFR Q787Q
    almost4years
    Reduced sensitivity for EGFR T790M mutations using the Idylla EGFR Mutation Test. (PubMed, J Clin Pathol)
    The Idylla EGFR Mutation Test has reduced sensitivity for the T790M mutation compared with NGS and ddPCR methods. The presence of an invalid T790M amplification curve may indicate a possible false negative result that warrants further testing by an orthogonal method.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR Q787Q
    |
    Idylla™ EGFR Mutation Test
    |
    Tagrisso (osimertinib)
    4years
    Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy. (PubMed, J Cancer Res Ther)
    We suggest that this rare synonymous mutation (EGFR-p. Q787Q) is a sensitive EGFR mutation in NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR Q787Q
    |
    erlotinib